GlobalData’s patient-based forecast predicts Tecvayli will reach a peak of $2.1bn in sales globally by 2030 in MM.
The regulator alleges that Morgan Stanley compliance policies failed to prevent four financial advisors from stealing millions of dollars from clients.
The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex (BVd) arm of DREAMM-7 versus a 60% rate with ...
Patients with newly diagnosed multiple myeloma experienced robust clinical activity when treated with Tecvayli (teclistamab) ...
Johnson & Johnson announces positive Phase II results for Tecvayli in newly diagnosed multiple myeloma, with all patients ...
Janssen-Cilag International NV, a Johnson & Johnson company, today announced new frontline data featuring TECVAYLI®â–¼ (teclistamab) from two investigational studies in patients with newly diagnosed ...
Johnson & Johnson (JNJ) announced new frontline data featuring TECVAYLI (teclistamab-cqyv) from two investigational studies in ...
Johnson & Johnson announced new frontline data featuring TECVAYLI from two investigational studies in patients with newly diagnosed ...
Teclistamab is an off-the-shelf (or ready to use) bispecific antibody. 6 Teclistamab, a subcutaneous injection, redirects T-cells through two cellular targets (BCMA and CD3) to activate the body's ...
For patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, the addition of Darzalex to VRd ...
Genmab's royalty revenues are expected to exceed $2.5 billion this year and potentially $4 billion at peak. See why I rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback